<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Pediatrics. Consilium Medicum</journal-id><journal-title-group><journal-title xml:lang="en">Pediatrics. Consilium Medicum</journal-title><trans-title-group xml:lang="ru"><trans-title>Педиатрия. Consilium Medicum</trans-title></trans-title-group></journal-title-group><issn publication-format="print">2658-6630</issn><issn publication-format="electronic">2658-6622</issn><publisher><publisher-name xml:lang="en">Consilium Medicum</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">692347</article-id><article-id pub-id-type="doi">10.26442/26586630.2025.3.203390</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Articles</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Статьи</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Neurokinin B and dynorphin affecting obese male adolescents behavior</article-title><trans-title-group xml:lang="ru"><trans-title>Модифицирующее влияние динорфинов и нейрокининов на поведение мальчиков-подростков с ожирением</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-4449-2786</contrib-id><name-alternatives><name xml:lang="en"><surname>Kelmanson</surname><given-names>Igor A.</given-names></name><name xml:lang="ru"><surname>Кельмансон</surname><given-names>Игорь Александрович</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>D. Sci. (Med.), Prof.</p></bio><bio xml:lang="ru"><p>д-р мед. наук, проф., проф. каф. детских болезней с клиникой лечебного фак-та Института медицинского образования</p></bio><email>iakelmanson@hotmail.com</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-4013-0785</contrib-id><name-alternatives><name xml:lang="en"><surname>Nikitina</surname><given-names>Irina L.</given-names></name><name xml:lang="ru"><surname>Никитина</surname><given-names>Ирина Леоровна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>D. Sci. (Med.), Prof.</p></bio><bio xml:lang="ru"><p>д-р мед. наук, проф., зав. каф. детских болезней с клиникой лечебного фак-та Института медицинского образования</p></bio><email>iakelmanson@hotmail.com</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-0740-2646</contrib-id><name-alternatives><name xml:lang="en"><surname>Vtornikova</surname><given-names>Natalia I.</given-names></name><name xml:lang="ru"><surname>Вторникова</surname><given-names>Наталья Игоревна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Аssistant</p></bio><bio xml:lang="ru"><p>ассистент каф. детских болезней с клиникой лечебного фак-та Института медицинского образования</p></bio><email>iakelmanson@hotmail.com</email><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Almazov National Medical Research Centre</institution></aff><aff><institution xml:lang="ru">ФГБУ «Национальный медицинский исследовательский центр им. В.А. Алмазова» Минздрава России</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2025-10-14" publication-format="electronic"><day>14</day><month>10</month><year>2025</year></pub-date><issue>3</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>290</fpage><lpage>297</lpage><history><date date-type="received" iso-8601-date="2025-10-07"><day>07</day><month>10</month><year>2025</year></date><date date-type="accepted" iso-8601-date="2025-10-07"><day>07</day><month>10</month><year>2025</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2025, Consilium Medicum</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2025, ООО "Консилиум Медикум"</copyright-statement><copyright-year>2025</copyright-year><copyright-holder xml:lang="en">Consilium Medicum</copyright-holder><copyright-holder xml:lang="ru">ООО "Консилиум Медикум"</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by-nc-sa/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://pediatria.orscience.ru/2658-6630/article/view/692347">https://pediatria.orscience.ru/2658-6630/article/view/692347</self-uri><abstract xml:lang="en"><p><bold>Background.</bold> Childhood obesity is still a trending healthcare problem. The incidence of obesity is growing worldwide regardless of any ongoing measures. Inefficiency of behavior, especially the eating behavior, intervention is one of the reasons of poor disease management. Kappa opioid receptor ligand dynorphin (DYN) and coupled KNDy mediator neurokinin B (NKB) seem not to be investigated enough as obese adolescents' behavior modulators.</p> <p><bold>Aim.</bold> The study was aimed to examine the modulating role of DYN and NKB on adolescent boys with obesity behavior.</p> <p><bold>Materials and methods.</bold> The study involved 84 adolescents aged 14–17 years: 57 with obesity (code E66.0, International Statistical Classification of Diseases and Related Health Problems 10th Revision) and 27 practically healthy individuals. The Achenbach System of Empirically Based Assessment (ASEBA) was utilized using Youth Self Report scales (YSR 11-18) to evaluate depressive, anxiety, somatic, attention deficit/hyperactivity, oppositional defiant and conduct problems. The Dutch Eating Behavior Questionnaire (DEBQ) was used to assess alterations. Laboratory studies included DYN and NKB blood levels evaluation using ELISA Kit for Big DYN and ELISA Kit for NKB correspondingly. Network analysis was performed to emphasize and visualize most relevant associations.</p> <p><bold>Results.</bold> The DYN level showed a significant negative correlation with attention problems and a positive correlation with NKB level. Network analysis showed that DYN level was strongly linked with negative bond to attention problems as, with a bit less strength, NKB also was. NKB and DYN levels were strongly linked in between either.</p> <p><bold>Conclusion.</bold> DYN is likely to play a modulating role in eating behavior, deviant and aggressive behavior especially in obese adolescents, acting as an additional obesity heterogeneity factor.</p></abstract><trans-abstract xml:lang="ru"><p><bold>Введение.</bold> Ожирение у детей и подростков становится все более актуальной проблемой здравоохранения. Распространенность детского ожирения увеличивается, значительно опережая проводимые по борьбе с ним мероприятия. Один из факторов, усложняющих контроль ожирения, – сложность коррекции поведения, в том числе пищевого (ПП). Недостаточно изучена роль лиганда κ-опиоидного рецептора динорфина (DYN) и сопряженного с ним нейромедиатора системы KNDy нейрокинина В (NKB) в регуляции поведения мальчиков-подростков с ожирением.</p> <p><bold>Цель.</bold> Изучить возможную модифицирующую роль DYN и NKB в поведении, включая ПП, у мальчиков-подростков с ожирением.</p> <p><bold>Материалы и методы.</bold> Обследованы 84 подростка в возрасте 14–17 лет: 57 с ожирением (код Е66.0, Международная классификация болезней 10-го пересмотра) и 27 практически здоровых. Для выявления симптомов нарушений поведения и эмоциональной сферы использовали опросник Ахенбаха (Youth Self Report – YSR 11-18). Для оценки отдельных вариантов изменения ПП, включая ограничительное, эмоциональное и экстернальное, применяли голландский опросник ПП (The Dutch Eating Behavior Questionnaire – DEBQ). Лабораторное исследование включало определение уровней DYN и NKB в плазме крови. Для статистической обработки применяли сетевой анализ.</p> <p><bold>Результаты.</bold> Уровень DYN значимо отрицательно коррелировал с выраженностью нарушения внимания и значимо положительно – с уровнем NKB. В ходе сетевого анализа установлены связи между показателями поведения и эмоций. Уровень DYN оказался связан заметной непосредственной отрицательной связью с нарушениями внимания, с которыми менее выраженной связью той же направленности связан уровень NKB. Между нейромедиаторами также наблюдалась выраженная положительная связь.</p> <p><bold>Заключение.</bold> DYN вносят модицифирующий вклад в поведение подростков, в частности в ПП, агрессивное и девиантное поведение, особенно у пациентов с ожирением, и участвуют в формировании гетерогенности этой патологии.</p></trans-abstract><kwd-group xml:lang="en"><kwd>dynorphin</kwd><kwd>neurokinin B</kwd><kwd>aggressive behavior</kwd><kwd>eating behavior</kwd><kwd>obesity</kwd><kwd>adolescents</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>динорфин</kwd><kwd>нейрокинин В</kwd><kwd>агрессивное поведение</kwd><kwd>пищевое поведение</kwd><kwd>ожирение</kwd><kwd>подростки</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Bixby H, Mishra A, Martinez AR. Worldwide levels and trends in childhood obesity, in Childhood Obesity. Academic Press, 2025.</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Cunningham SA, Hardy ST, Jones R, et al. Changes in the Incidence of Childhood Obesity. Pediatrics. 2022;150(2):e2021053708. DOI:10.1542/peds.2021-053708</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Spinelli A, Buoncristiano M, Nardoneet P, et al. Thinness, overweight, and obesity in 6 to 9 year old children from 36 countries: The World Health Organization European Childhood Obesity Surveillance Initiative-COSI 2015–2017. Obes Rev. 2021;22(Suppl. 6):e13214. DOI:10.1111/obr.13214</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Jha S, Mehendale AM. Increased Incidence of Obesity in Children and Adolescents Post-COVID-19 Pandemic: A Review Article. Cureus. 2022;14(9):e29348. DOI:10.7759/cureus.29348</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Boswell N, Byrne R, Davies P. Aetiology of eating behaviours: A possible mechanism to understand obesity development in early childhood. Neurosci Biobehav Rev. 2018;95:438-48. DOI:10.1016/j.neubiorev.2018.10.020</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Kansra AR, Lakkunarajah S, Jay MS. Childhood and Adolescent Obesity: A Review. Front Pediatr. 2021;8:581461. DOI:10.3389/fped.2020.581461</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Nikitina IL, Vtornikova NI, Kelmanson IA. Clinical heterogeneity of sleep quality, emotional and behavioral characteristics, and eating habits in adolescents with obesity: A cluster analysis. Eur J Pediatr. 2024;183(4):1571-84. DOI:10.1007/s00431-023-05406-1</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Вторникова Н.И., Никитина И.Л., Кельмансон И.А. Гетерогенность метаболических фенотипов у мальчиков-подростков с экзогенно-конституциональной формой ожирения. Экспериментальная и клиническая гастроэнтерология. 2024;6:20-30 [Vtornikova NI, Nikitina IL, Kelmanson IA. Heterogeneity of metabolic phenotypes in adolescent boys with obesity due to excess calories. Eksperimentalnaia i Klinicheskaia Gastroenterologiia. 2024;6:20-30 (in Russian)]. DOI:10.31146/1682-8658-ecg-226-6-20-30</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Uenoyama Y, Nagae M, Tsuchida H, et al. Role of KNDy neurons expressing kisspeptin, neurokinin B, and dynorphin A as a GnRH pulse generator controlling mammalian reproduction. Front Endocrinol (Lausanne). 2021;12:724632. DOI:10.3389/fendo.2021.724632.021;12:724632</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Roddick C, Harris M, Hofman PL. The Metabolic Programming of Pubertal Onset. Clin Endocrinol (Oxf). 2025;102(5):526-38. DOI:10.1111/cen.15138</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Никитина И.Л., Юхлина Ю.Н., Саракаева Л.Р., и др. Современная концепция нейроэндокринной и эпигенетической регуляции старта пубертата и полового развития. Трансляционные исследования роли лиганд-рецепторной системы кисспептина kiss/kiss1r. Трансляционная медицина. 2020;7(5):62-80 [Nikitina IL, Yuchlina YuN, Sarakaeva LR. Modern concept of neuroendocrine and epigenetic regulation of the onset of puberty and sexual development. Translational studies on the role of the kiss/kiss1r system. Transliatsionnaia Meditsina. 2020;7(5):62-80 (in Russian)]. DOI:10.18705/2311-4495-2020-7-5-62-80</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Shi L, Jiang Z, Zhang L. Childhood obesity and central precocious puberty. Front Endocrinol (Lausanne). 2022;13:1056871.</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Shippenberg TS, Zapata A, Chefer VI. Dynorphin and the pathophysiology of drug addiction. Pharmacol Ther. 2007;116(2):306-21. DOI:10.1016/j.pharmthera.2007.06.011</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Pliakas AM, Carlson RR, Neve RL, et al. Altered responsiveness to cocaine and increased immobility in the forced swim test associated with elevated cAMP response element-binding protein expression in nucleus accumbens. J Neurosci. 2001;21(18):7397-403. DOI:10.1523/JNEUROSCI.21-18-07397.2001</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Mague SD, Pliakas AM, Todtenkopf MS, et al. Antidepressant-like effects of kappa-opioid receptor antagonists in the forced swim test in rats. J Pharmacol Exp Ther. 2003;305(1):323-30. DOI:10.1124/jpet.102.046433</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Crowley NA, Bloodgood DW, HardawayJ, et al. Dynorphin controls the gain of an amygdalar anxiety circuit. Cell Rep. 2016;14(12):2774-83. DOI:10.1016/j.celrep.2016.02.069</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Bruchas MR, Land BB, Chavkin C. The dynorphin/kappa opioid system as a modulator of stress-induced and pro-addictive behaviors. Brain Res. 2010;1314: 44-55. DOI:10.1016/j.brainres.2009.08.062</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Land BB, Bruchas MR, Lemos JC, et al. The dysphoric component of stress is encoded by activation of the dynorphin kappa-opioid system. J Neurosci. 2008;28(2):407-14. DOI:10.1523/JNEUROSCI.4458-07.2008</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Khawaja XZ, Chattopadhyay AK, Green IC. Increased β-endorphin and dynorphin concentrations in discrete hypothalamic regions of genetically obese (ob/ob) mice. Brain Res. 1991;555(1):164-8. DOI:10.1016/0006-8993(91)90874-u</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Berman Y, Devi L, Spangler R, et al. Chronic food restriction and streptozotocin-induced diabetes differentially alter prodynorphin mRNA levels in rat brain regions. Mol Brain Res. 1997;46(1):25-30. DOI:10.1016/s0169-328x(96)00175-1</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Nakao K, Iwata K, Takeshita T, Ozawa H. Expression of hypothalamic kisspeptin, neurokinin B, and dynorphin A neurons attenuates in female Zucker fatty rats. Neurosci Lett. 2018;665:135-9. DOI:10.1016/j.neulet.2017.12.002</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Minabe S, Iwata K, Tsuchida H, et al. Effect of diet-induced obesity on kisspeptin-neurokinin B-dynorphin A neurons in the arcuate nucleus and luteinizing hormone secretion in sex hormone-primed male and female rats. Peptides. 2021;142:170546. DOI:10.1016/j.peptides.2021.170546</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Karkhanis A, Holleran KM, Jones SR. Dynorphin/kappa opioid receptor signaling in preclinical models of alcohol, drug, and food addiction. Int Rev Neurobiol. 2017;136: 53-88. DOI:10.1016/bs.irn.2017.08.001</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>Cicuendez B, Perez-Garcia J, Folgueira C. A Combination of a Dopamine Receptor 2 Agonist and a Kappa Opioid Receptor Antagonist Synergistically Reduces Weight in Diet-Induced Obese Rodents. Nutrients. 2024;16(3):424. DOI:10.3390/nu16030424</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>Ghule A, Racz I, Bilkei-Gorzo A, et al. Modulation of feeding behavior and metabolism by dynorphin. Scientific Reports. 2020;10(1):3821. DOI:10.1038/s41598-020-60518-0</mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation>Yang JA, Yasrebi A, Snyder M, Roepke TA. The interaction of fasting, caloric restriction, and diet-induced obesity with 17β-estradiol on the expression of KNDy neuropeptides and their receptors in the female mouse. Mol Cell Endocrinol. 2016;437:35-50. DOI:10.1016/j.mce.2016.08.008</mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation>Dudek M, Kołodziejski PA, Pruszyńska-Oszmałek E, et al. Effects of orchidectomy and testosterone replacement on numbers of kisspeptin-, neurokinin B-, and dynorphin A-immunoreactive neurones in the arcuate nucleus of the hypothalamus in obese and diabetic rats. J Neuroendocrinol. 2017;29(2). DOI:10.1111/jne.12453</mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation>Шагиахметов Ф.Ш., Проскурякова Т.В., Шамакина И.Ю. Динорфин/каппа-опиоидная система мозга как перспективная мишень для терапии зависимости от психоактивных веществ. Нейрохимия. 2015;32:285-94 [Shagiakhmetov FS, Proskuryakova TV, Shamakina IY.The dynorphin/kappa-opioid system of the brain as a promising target for therapy for dependence on psychoactive substances. Neirokhimiia. 2015;32:285-94 (in Russian)]. DOI:10.7868/S1027813315040159</mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation>Paris JJ, Reilley KJ, McLaughlin JP. Kappa Opioid Receptor-Mediated Disruption of Novel Object Recognition: Relevance for Psychostimulant Treatment. J Addict Res Ther. 2011;S4. DOI:10.4172/2155-6105.S4-007</mixed-citation></ref><ref id="B30"><label>30.</label><mixed-citation>Abraham AD, Fontaine HM, Song AJ, et al. κ-Opioid Receptor Activation in Dopamine Neurons Disrupts Behavioral Inhibition. Neuropsychopharmacology. 2018;43(2): 362-72. DOI:10.1038/npp.2017.133</mixed-citation></ref><ref id="B31"><label>31.</label><mixed-citation>Escobar A, Casanova JP, Andres ME, Fuentealba JA. Crosstalk Between Kappa Opioid and Dopamine Systems in Compulsive Behaviors. Front Pharmacol. 2020;11:57. DOI:10.3389/fphar.2020.00057</mixed-citation></ref><ref id="B32"><label>32.</label><mixed-citation>Carey AN, Lyons AM, Shay CF, et al. Endogenous κ Opioid Activation Mediates Stress-Induced Deficits in Learning and Memory. J Neurosci. 2009;29(13):4293. DOI:10.1523/JNEUROSCI.6146-08.2009</mixed-citation></ref><ref id="B33"><label>33.</label><mixed-citation>Mohammadkhani A, Qiao M, Borgland SL. Distinct neuromodulatory effects of endogenous orexin and dynorphin corelease on projection-defined ventral tegmental dopamine neurons. J Neurosci. 2024;44(39). DOI:10.1523/JNEUROSCI.0682-24.2024</mixed-citation></ref><ref id="B34"><label>34.</label><mixed-citation>Faul F, Erdfelder E, Lang AG, Buchner A. G*Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav Res Methods. 2007;39(2):175-91. DOI:10.3758/bf03193146</mixed-citation></ref><ref id="B35"><label>35.</label><mixed-citation>Marshall WA, Tanner JM. Variations in the Pattern of Pubertal Changes in Boys. Arch Dis Child. 1970;45(239):13. DOI:10.1136/adc.45.239.13</mixed-citation></ref><ref id="B36"><label>36.</label><mixed-citation>Merg F, Filliol D, Usynin I, et al. Big dynorphin as a putative endogenous ligand for the kappa-opioid receptor. J Neurochem. 2006;97(1):292-301. DOI:10.1111/j.1471-4159.2006.03732.x</mixed-citation></ref><ref id="B37"><label>37.</label><mixed-citation>Achenbach TM, Rescorla LA. Manual for the ASEBA School-age Forms &amp; Profiles: An Integrated System of Multi-informant Assessment. Publicaciones de Psicologia Aplicada: Serie Menor. Burlington: ASEBA, 2001.</mixed-citation></ref><ref id="B38"><label>38.</label><mixed-citation>Колмагорова А., Слободская Е., Киншт И.А. Оценка психического здоровья в раннем возрасте. Бюллетень Сибирского отделения Российской академии медицинских наук. 2007(3):46-52 [Kolmagorova AV, Slobodskaya HR, Kinscht LA. Mental health assessment in early childhood. Biulleten Sibirskogo Otdeleniia Rossiiskoi Akademii Meditsinskikh Nauk. 2007(3):46-52 (in Russian)]. EDN: IBVCDT</mixed-citation></ref><ref id="B39"><label>39.</label><mixed-citation>van Strien T, Frijters J, Bergers G, Defares P. The Dutch Eating Behavior Questionnaire (DEBQ) for assessment of restrained, emotional, and external eating behavior. Int J Eat Disord. 1986;5(2):295-315. DOI:10.1002/1098-108X(198602)5:2&lt;295::AID-EAT2260050209&gt;3.0.CO;2-T</mixed-citation></ref><ref id="B40"><label>40.</label><mixed-citation>Borisenkov MF, Popov SV, Pecherkina AA, et al. Food addiction in young adult residents of Russia: Associations with emotional and anthropometric characteristics. Eur Eat Disord Rev. 2020;28(4):465-72. DOI:10.1002/erv.2731</mixed-citation></ref><ref id="B41"><label>41.</label><mixed-citation>Epskamp S, Fried EI. A tutorial on regularized partial correlation networks. Psychol Methods. 2018;23(4):617-34. DOI:10.1037/met0000167</mixed-citation></ref><ref id="B42"><label>42.</label><mixed-citation>Abad J, Santacana M, Gomez-Benito J. Emotional and Behavioral Problems as Measured by the YSR: Gender and Age Differences in Spanish Adolescents. Eur J sychol Assess. 2002;18:149-57. DOI:10.1027//1015-5759.18.2.157</mixed-citation></ref><ref id="B43"><label>43.</label><mixed-citation>Roussos A, Francis K, Zoubou V, et al. The standardization of Achenbach's Youth Self-Report in Greece in a national sample of high school students. Eur Child Adolesc Psychiatry. 2001;10(1):47-53. DOI:10.1007/s007870170046</mixed-citation></ref><ref id="B44"><label>44.</label><mixed-citation>Braet C, Claus L, Goossens L, et al. Differences in Eating Style between Overweight and Normal-Weight Youngsters. J Health Psychol. 2008;13(6):733-43. DOI:10.1177/1359105308093850</mixed-citation></ref><ref id="B45"><label>45.</label><mixed-citation>Nagl M, Hilbert A, de Zwaan M, et al. The German Version of the Dutch Eating Behavior Questionnaire: Psychometric Properties, Measurement Invariance, and Population-Based Norms. PLOS ONE. 2016;11(9):e0162510. DOI:10.1371/journal.pone.0162510</mixed-citation></ref><ref id="B46"><label>46.</label><mixed-citation>Chou TC, Lee CE, Lu J, et al. Orexin (Hypocretin) Neurons Contain Dynorphin. J Neurosci. 2001;21(19):RC168. DOI:10.1523/JNEUROSCI.21-19-j0003.2001</mixed-citation></ref><ref id="B47"><label>47.</label><mixed-citation>Matzeu A, Kallupi M, George O, et al. Dynorphin Counteracts Orexin in the Paraventricular Nucleus of the Thalamus: Cellular and Behavioral Evidence. Neuropsychopharmacology. 2018;43(5):1010-20. DOI:10.1038/npp.2017.250</mixed-citation></ref><ref id="B48"><label>48.</label><mixed-citation>Mattar P, Uribe-Cerda S, Pezoa C, et al. Brain site-specific regulation of hedonic intake by orexin and DYN peptides: role of the PVN and obesity. Nutr Neurosci. 2022;25(5):1105-14. DOI:10.1080/1028415X.2020.1840049</mixed-citation></ref><ref id="B49"><label>49.</label><mixed-citation>Abraham AD, Casello SM, Schattauer SS, et al. Release of endogenous dynorphin opioids in the prefrontal cortex disrupts cognition. Neuropsychopharmacology. 2021;46(13):2330-9. DOI:10.1038/s41386-021-01168-2</mixed-citation></ref><ref id="B50"><label>50.</label><mixed-citation>Cortese S, Moreira-Maia CR, St Fleur D, et al. Association Between ADHD and Obesity: A Systematic Review and Meta-Analysis. American J Psychiatry. 2016;173(1):34-43. DOI:10.1176/appi.ajp.2015.15020266</mixed-citation></ref><ref id="B51"><label>51.</label><mixed-citation>Cortese S, Tessari L. Attention-Deficit/Hyperactivity Disorder (ADHD) and Obesity: Update 2016. Curr Psychiatry Rep. 2017;19(1):4. DOI:10.1007/s11920-017-0754-1</mixed-citation></ref><ref id="B52"><label>52.</label><mixed-citation>Kooij J. ADHD and Obesity. Am J Psychiatry. 2016;173(1):1-2. DOI:10.1176/appi.ajp.2015.15101315</mixed-citation></ref><ref id="B53"><label>53.</label><mixed-citation>Nigg JT, Johnstone JM, Musser ED, et al. Attention-deficit/hyperactivity disorder (ADHD) and being overweight/obesity: New data and meta-analysis. Clin Psychol Rev. 2016;43:67-79. DOI:10.1016/j.cpr.2015.11.005</mixed-citation></ref><ref id="B54"><label>54.</label><mixed-citation>Martins-Silva T, Dos Santos Vaz J, Genro JP, et al. Obesity and ADHD: Exploring the role of body composition, BMI polygenic risk score, and reward system genes. J Psychiatr Res. 2021;136:529-36. DOI:10.1016/j.jpsychires.2020.10.026</mixed-citation></ref><ref id="B55"><label>55.</label><mixed-citation>Moon C, Marion M, Thanos PK, Steiner H. Fluoxetine Potentiates Oral Methylphenidate-Induced Gene Regulation in the Rat Striatum. Mol Neurobiol. 2021;58:4856-70. DOI:10.1007/s12035-021-02466-y</mixed-citation></ref></ref-list></back></article>
